Contact this trialFirst, we need to learn more about you.
Hypomethylating Agent
Oral Azacitidine + Durvalumab for Myelodysplastic Syndrome
Recruiting1 awardPhase 2
Pittsburgh, Pennsylvania
This trial is evaluating the safety and efficacy of oral azacitidine in subjects with myelodysplastic syndromes who failed to achieve an objective response to injectable hypomethylating agent treatment. An extension phase has been added to allow subjects who are currently receiving oral azacitidine and demonstrating clinical benefit to continue receiving the treatment until they meet the criteria for study discontinuation.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.